Lin Elizabeth Yeu Insider Trading Activity

Average Profitability
11.85%
Insider Buys Quantity
3
Insider Buys Sum
$556,306.40
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Lin Elizabeth Yeu

According to the SEC Form 4 filings, Lin Elizabeth Yeu, being in a position of

  1. Chief Medical Officer at Tarsus Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 35730 shares for $2.96M,
    over all time since 2022-09-14, has bought 27906 shares for $456,306, and sold 36736 shares for $3M.

Biography of Lin Elizabeth Yeu

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$2,955,3248100

Comparison of Insiders on Amount of Buys and Sells

2026-09-04SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
13,953
0.031%
$87.50$1.22M-18.16%
2026-09-04SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
6,977
0.0151%
$85.00$593,045-18.16%
2026-09-02SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
6,977
0.0157%
$80.00$558,160-10.1%
2026-09-01SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
4,601
0.0107%
$73.86$339,830+0.51%
2026-03-19SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
390
0.0009%
$67.00$26,130+0.38%
2026-03-18SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
379
0.0009%
$68.71$26,041-1.88%
2026-03-17SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
375
0.0009%
$69.42$26,033-3.99%
2025-12-16SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
2,078
0.005%
$79.50$165,201-12.83%
2025-06-16SaleTarsus Pharmaceuticals, Inc.
TARS
Chief Medical Officer
1,006
0.0024%
$41.08$41,326+57.52%
2023-09-21PurchaseSTAAR Surgical Company
STAA
director
2,500
0.0052%
$40.00$100,000-3.35%
2023-08-15PurchaseTarsus Pharmaceuticals, Inc.
TARS
director
9,506
0.035%
$16.80$159,701+54.29%
2022-09-14PurchaseTarsus Pharmaceuticals, Inc.
TARS
director
18,400
0.0684%
$16.12$296,606-0.18%
Total: 12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.